Valeant Pharma (VRX): Salix Sale Resolves Nothing - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Valeant (VRX) Would Not Be Selling Core Assets if All Was Well - Wells Fargo's Maris
November 2, 2016 10:23 AM EDTWells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX) following reports it may be close to a deal to divest Salix for approximately $10 billion. VRX issued a statement that it is in discussions with third parties for various divestitures including but not limited to Salix. Maris said selling Salix is like selling the stove to keep the restaurant.
"This is... More
